Kagocel wins Russian Pharma Awards again

Kagocel wins Russian Pharma Awards again

On December 16, the antiviral drug Kagocel was for the seventh time proclaimed winner of the annual Russian Pharma Awards in the category «Antiviral agent No. 1 in Russia against influenza and ARVI for adults and children from the age of three».

This award means recognition by professionals since voting for the nominees takes place in the largest professional social network, Doctor at Work. More than 550,000 doctors choose the best drugs in 20 categories. Kagocel product manager, Anna Dakhina, commented on the event: «Winning in the Russian Pharma Awards to us means high assessment of Russian practitioners. We are very pleased that despite the wide range of antiviral drugs, doctors still choose Kagocel. Our main task is to help them fight such diseases of great social significance as influenza and ARVI.»

The difficult year 2020 was a year of new challenges and opportunities for the manufacturer of the drug, the Nearmedic Pharma company. The company conducted laboratory studies of Kagocel’s effectiveness against the SARS-CoV-2 virus which yielded positive results, with tests being continued in real clinical practice. By this time, the study has already reached its third phase. This is a double blind, placebo-controlled trial that meets all GCP standards. The company plans to obtain the results by August 31, 2021. «A full-fledged clinical trial takes a long time, and although we are sure of the result, in order to start clinical practice, we need to obtain accurate and reliable data,» said Anna Dakhina.

In addition, in the fall of this year, a new large package of Kagocel containing 30 tablets was introduced. It represents a course of treatment for colds and flu for one adult and one child over three years old, and is also a complete course for the treatment of herpes in adults as part of combination therapy.

It should be reminded that the antiviral drug Kagocel was recognized as the winner of the Russian Pharma Awards in 2014, 2015, 2016, 2017, 2018, 2019, and 2020.

The drug belongs to interferon inducers, a family of drugs that stimulate the production of the body’s own interferons, that is specific proteins that block the reproduction of pathogenic viruses. The use of interferon inducers is included in various clinical recommendations of the Russian Federation’s Ministry of Health for the treatment and prevention of influenza and ARVI in adults and children. Their use for the treatment of any undifferentiated acute respiratory infections during the pandemic, as well as for planned and emergency prevention, is also included in the Provisional Guidelines of the RF Ministry of Health titled Prevention, diagnosis and treatment of the new coronavirus infection COVID-19.